The abstract is read at the publisher; the summary is JClub's.
In a phase 2 open-label single-arm trial in persons with Down syndrome, tofacitinib met its primary safety endpoint and showed a safety profile similar to the general population.
- Why it matters: Down syndrome involves immune dysregulation with hyperactive interferon/JAK/STAT signaling, and there is a need for safe ways to attenuate these pathways.
- What they did: Participants received tofacitinib for up to 9 months with extensive safety monitoring plus biomarker, skin pathology, and neuropsychological assessments, alongside multi-omics pathway analyses.
- The result: Tofacitinib decreased interferon scores, cytokine scores, and neurotoxic immunometabolites without overt immune suppression, with exploratory improvements in immunodermatological conditions and neuropsychological measures.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.